SLC5A2 and type 2 diabetes mellitus: Renin-angiotensin-aldosterone system (RAAS) blockers and new antidiabetic agents with cardio- and nephroprotective effects (sodium-glucose cotransporter 2 inhibitors (SGLT2i) - and glucagon-like peptide-1 receptor agonists – (GLP-1 RA)) have drastically changed the prognosis of T2DM patients with kidney disease, reducing cardiovascular events and mortality, slowing the decline of eGFR, and delaying the need for renal replacement therapy (21–23).